Home > Compound List > Product Information
Probenecid_Molecular_structure_CAS_57-66-9)
Click picture or here to close

Probenecid

Catalog No. DB01032 Name DrugBank
CAS Number 57-66-9 Website http://www.ualberta.ca/
M. F. C13H19NO4S Telephone (780) 492-3111
M. W. 285.35926 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 904

SYNONYMS

IUPAC name
4-(dipropylsulfamoyl)benzoic acid
IUPAC Traditional name
probenecid
Brand Name
Probexin
Proben-C
Synergid R
Apurina
Benemid
Benuryl
Col-Probenecid
Probampacin
Probecid
Proben
Probenemid
Prolongine
Tubophan
Uricosid
Benecid
Colbenemid
Polycillin-PRB
Probalan
Synonyms
probenicid
Probenecid Acid

DATABASE IDS

CAS Number 57-66-9
PubChem SID 46506554
PubChem CID 4911

PROPERTIES

Hydrophobicity(logP) 2.3
Solubility 27.1 mg/L

DETAILS

Description (English)
Item Information
Drug Groups approved
Description The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. [PubChem]
Indication For the reduction of serum uric acid concentrations in chronic gouty arthritis and tophaceous gout in patients with frequent disabling gout attacks. Has also been effectively used to promote uric acid excretion in hyperuricemia secondary to the administration of thiazide and related diuretics.
Pharmacology Probenecid is a uricosuric and renal tubular blocking agent and is used in combination with colchicine to treat chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. It inhibits the reabsorption of urate at the proximal convoluted tubule, thus increasing the urinary excretion of uric acid and decreasing serum urate levels. Effective uricosuria reduces the miscible urate pool, retards urate deposition, and promotes resorption of urate deposits. At the proximal and distal tubles, probenecid competitively inhibits the secretion of many weak organic acids including penicillins, most cephalosporins, and some other β-lactam antibiotics. This results in an increase in the plasma concentrations of acidic drugs eliminated principally by renal secretion, but only a slight increase if the drug is eliminated mainly by filtration. Thus, the drug can be used for therapeutic advantages to increase concentrations of certain β-lactam antibiotics in the treatment of gonorrhea, neurosyphilis, or pelvic inflammatory disease (PID).
Affected Organisms
Humans and other mammals
Half Life 6-12 hours
Protein Binding 75-95%
Elimination Excreted principally in the urine as monoacyl glucuronide and unchanged drug. Alkalinization of urine increases renal probenecid excretion.
References
Butler D: Wartime tactic doubles power of scarce bird-flu drug. Nature. 2005 Nov 3;438(7064):6. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES

  • Butler D: Wartime tactic doubles power of scarce bird-flu drug. Nature. 2005 Nov 3;438(7064):6. Pubmed